A Study To Assess The Efficacy and Safety of HH-120 Nasal Spray for the Treatment of Mild COVID-19
Status:
Recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled Phase 2 study in participants over the
age of 18 years with mild COVID-19. The main purpose of this study is to evaluate the effect
on viral load clearance and clinical recovery, and safety of HH-120 nasal spray in
participants over the age of 18 years with mild COVID-19 (according to the FDA definition,
2021).